Sequence-dependent effect of gemcitabine and cisplatin on A549 non-small-cell lung cancer cells

Molecular Medicine Reports

Volumn 8, Issue 1, 2013, Pages 221-226

  Tang, Yu ^a   Wang, Yan ^a   Teng, Xiuzhi ^b  

^a LIAONING CANCER HOSPITAL AND INSTITUTE   (China)

^b Central Hospital of Liaoning Electric Power   (China)

Author keywords

Cisplatin; Combination chemotherapy; Gemcitabine; Sequence dependent effect

Indexed keywords

CISPLATIN; GEMCITABINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LUNG NEOPLASMS;

EID: 84878916996     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1495     Document Type: Article

References (27)

1. Kroep JR, Peters GJ, van Moorsel CJ, et al: Gemcitabine-cisplatin: A schedule finding study. Ann Oncol 10: 1503-1510, 1999. (Pubitemid 30017063)
2. No authors listed: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 311: 899-909, 1995.
3. No authors listed: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15: 2996-3018, 1997.
4. Berghmans T, Paesmans M, Lalami Y, et al: Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38: 111-121, 2002. (Pubitemid 35157753)
5. Braakhuis BJ, van Dongen GA, Vermorken JB and Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer. Cancer Res 51: 211-214, 1991.
6. van Moorsel CJ, Veerman G, Bergman AM, et al: Combination chemotherapy studies with gemcitabine. Semin Oncol 24 (2 Suppl 7): S7-17-S7-23, 1997.
7. Peters GJ, Ruiz van Haperen VW, Bergman AM, et al: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23 (5 Suppl 10): 16-24, 1996. (Pubitemid 26362190)
8. Braakhuis BJ, Ruiz van Haperen VW, Welters MJ and Peters GJ: Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31A: 2335-2340, 1995. (Pubitemid 26050580)
9. Bergman AM, Ruiz van Haperen VW, Veerman G, et al: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530, 1996. (Pubitemid 26099172)
10. Tsai CM, Chang KT, Chen JY, et al: Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. Cancer Res 56: 794-801, 1996.
11. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
12. McKeage MJ: Comparative adverse effect profiles of platinum drugs. Drug Saf 13: 228-244, 1995.
13. Bunn PA Jr.: Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? J Clin Oncol 20: 23S-33S, 2002.
14. Voigt W, Bulankin A, Müller T, et al: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 6: 2087-2093, 2000. (Pubitemid 30305109)
15. van Moorsel CJ, Pinedo HM, Veerman G, et al: Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 35: 808-814, 1999. (Pubitemid 29258152)
16. Crinò L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lungcancer: a phase II study. J Clin Oncol 15: 297-303, 1997. (Pubitemid 27020587)
17. Zanellato I, Boidi CD, Lingua G, et al: In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects. Cancer Chemother Pharmacol 67: 265-273, 2010.
18. Voigt W, Bulankin A, Müller T, et al: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 6: 2087-2093, 2000. (Pubitemid 30305109)
19. Jackson RC: Amphibolic drug combinations: the design of selective antimetabolite protocols based upon the kinetic properties of multienzyme systems. Cancer Res 53: 3998-4003, 1993.
20. Eastman A: The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34: 155-166, 1987.
21. Bunch RT, and Eastman A: 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ 8: 779-788, 1997. (Pubitemid 27287809)
22. Karagiannis TC and El-Osta A: Double-strand breaks: signaling pathways and repair mechanisms. Cell Mol Life Sci 61: 2137-2147, 2004. (Pubitemid 39280110)
23. Bergstralh DT and Sekelsky J: Interstrand crosslink repair: can XPF-ERCC1 be let off the hook? Trends Genet 24: 70-76, 2008.
24. Pérol M, Chouaid C, Pérol D, et al: Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30: 3516-3524, 2012.
25. Hida T, Ogawa S, Park JC, et al: Gefitinib for the treatment of non-small-cell lung cancer. Expert Rev Anticancer Ther 9: 17-35, 2009.
26. Ozaki K, Kishikawa F, Tanaka M, et al: Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci 99: 376-384, 2008. (Pubitemid 351228495)
27. Donadelli M, Costanzo C, Beghelli S, et al: Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. Biochim Biophys Acta 1773: 1095-1106, 2007. (Pubitemid 46898677)